7:01 am Bristol-Myers presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR12 rates of up to 90% among broad range of genotype 1b hepatitis C patients – HedgeChatter

7:01 am Bristol-Myers presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR12 rates of up to 90% among broad range of genotype 1b hepatitis C patients

11 Apr

7:01 am Bristol-Myers presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR12 rates of up to 90% among broad range of genotype 1b hepatitis C patients

Bystocknews BMY, stock Comments Off

View todays social media effects on BMY

View the latest stocks trending across Twitter. Click to view dashboard

See who Bristol is hiring next, click here to view

Author